866-997-4948(US-Canada Toll Free)

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 76 Pages


Global Markets Directs, \'Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer). 

Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Transitional Cell Cancer (Urothelial Cell Cancer).
  • A review of the Transitional Cell Cancer (Urothelial Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Transitional Cell Cancer (Urothelial Cell Cancer).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Transitional Cell Cancer (Urothelial Cell Cancer) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Transitional Cell Cancer (Urothelial Cell Cancer) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer) 8
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics under Development by Companies 10
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Products under Development by Companies 14
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Development 16
Bristol-Myers Squibb Company 16
Boehringer Ingelheim GmbH 17
Eli Lilly and Company 18
Novartis AG 19
AEterna Zentaris Inc. 20
Spectrum Pharmaceuticals, Inc. 21
Innate Therapeutics Limited 22
PharmaMar, S.A. 23
Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
AEZS-108 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
brivanib alaninate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
volasertib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ramucirumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
pralatrexate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
dovitinib lactate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
PM-00104 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Docetaxel + Zactima - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
bevacizumab + [gemcitabine hydrochloride] + [cisplatin] - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 48
buparlisib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Survivin-Derived Peptide Vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
bevacizumab + [cisplatin] + [doxorubicin] + [methotrexate] + [vinblastine sulfate] - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
vandetanib + [carboplatin] + [gemcitabine] - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
vandetanib + [carboplatin] + [gemcitabine] - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MIS-416 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
olaparib + [cisplatin] + [gemcitabine hydrochloride] - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Drug Profile Updates 62
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Discontinued Products 72
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Dormant Products 73
Transitional Cell Cancer (Urothelial Cell Cancer) - Product Development Milestones 74
Featured News & Press Releases 74
May 16, 2012: Sanofi To Present Abstracts On Jevtana At 2012 American Society Of Clinical Oncology Annual Meeting 74

Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Table


Number of Products Under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H1 2013 8
Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Number of Products under Investigation by Universities/Institutes, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Bristol-Myers Squibb Company, H1 2013 16
Boehringer Ingelheim GmbH, H1 2013 17
Eli Lilly and Company, H1 2013 18
Novartis AG, H1 2013 19
AEterna Zentaris Inc., H1 2013 20
Spectrum Pharmaceuticals, Inc., H1 2013 21
Innate Therapeutics Limited, H1 2013 22
PharmaMar, S.A., H1 2013 23
Assessment by Monotherapy Products, H1 2013 24
Assessment by Combination Products, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 29
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Drug Profile Updates 62
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Discontinued Products 72
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Dormant Products 73

List of Chart


Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H1 2013 8
Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 24
Assessment by Combination Products, H1 2013 25
Assessment by Route of Administration, H1 2013 26
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Molecule Type, H1 2013 28
Assessment by Stage and Molecule Type, H1 2013 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *